These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

440 related items for PubMed ID: 21868512

  • 1. The mTOR inhibitor RAD001 sensitizes tumor cells to the cytotoxic effect of carboplatin in breast cancer in vitro.
    Liu H, Zang C, Schefe JH, Schwarzlose-Schwarck S, Regierer AC, Elstner E, Schulz CO, Scholz C, Possinger K, Eucker J.
    Anticancer Res; 2011 Sep; 31(9):2713-22. PubMed ID: 21868512
    [Abstract] [Full Text] [Related]

  • 2. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.
    Liu H, Scholz C, Zang C, Schefe JH, Habbel P, Regierer AC, Schulz CO, Possinger K, Eucker J.
    Anticancer Res; 2012 May; 32(5):1627-37. PubMed ID: 22593441
    [Abstract] [Full Text] [Related]

  • 3. Akt and p53 are potential mediators of reduced mammary tumor growth by cloroquine and the mTOR inhibitor RAD001.
    Loehberg CR, Strissel PL, Dittrich R, Strick R, Dittmer J, Dittmer A, Fabry B, Kalender WA, Koch T, Wachter DL, Groh N, Polier A, Brandt I, Lotz L, Hoffmann I, Koppitz F, Oeser S, Mueller A, Fasching PA, Lux MP, Beckmann MW, Schrauder MG.
    Biochem Pharmacol; 2012 Feb 15; 83(4):480-8. PubMed ID: 22142888
    [Abstract] [Full Text] [Related]

  • 4. Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells.
    Treeck O, Wackwitz B, Haus U, Ortmann O.
    Gynecol Oncol; 2006 Aug 15; 102(2):292-9. PubMed ID: 16443261
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
    deGraffenried LA, Friedrichs WE, Russell DH, Donzis EJ, Middleton AK, Silva JM, Roth RA, Hidalgo M.
    Clin Cancer Res; 2004 Dec 01; 10(23):8059-67. PubMed ID: 15585641
    [Abstract] [Full Text] [Related]

  • 6. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer.
    Boulay A, Rudloff J, Ye J, Zumstein-Mecker S, O'Reilly T, Evans DB, Chen S, Lane HA.
    Clin Cancer Res; 2005 Jul 15; 11(14):5319-28. PubMed ID: 16033851
    [Abstract] [Full Text] [Related]

  • 7. The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study.
    Macaskill EJ, Bartlett JM, Sabine VS, Faratian D, Renshaw L, White S, Campbell FM, Young O, Williams L, Thomas JS, Barber MD, Dixon JM.
    Breast Cancer Res Treat; 2011 Aug 15; 128(3):725-34. PubMed ID: 20941539
    [Abstract] [Full Text] [Related]

  • 8. Synergistic anti-tumor effects of RAD001 with MEK inhibitors in neuroendocrine tumors: a potential mechanism of therapeutic limitation of mTOR inhibitor.
    Iida S, Miki Y, Ono K, Akahira J, Nakamura Y, Suzuki T, Sasano H.
    Mol Cell Endocrinol; 2012 Mar 05; 350(1):99-106. PubMed ID: 22178087
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer.
    Liu H, Zang C, Emde A, Planas-Silva MD, Rosche M, Kühnl A, Schulz CO, Elstner E, Possinger K, Eucker J.
    Eur J Pharmacol; 2008 Sep 04; 591(1-3):43-51. PubMed ID: 18588872
    [Abstract] [Full Text] [Related]

  • 12. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation.
    Beuvink I, Boulay A, Fumagalli S, Zilbermann F, Ruetz S, O'Reilly T, Natt F, Hall J, Lane HA, Thomas G.
    Cell; 2005 Mar 25; 120(6):747-59. PubMed ID: 15797377
    [Abstract] [Full Text] [Related]

  • 13. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.
    Ewald F, Grabinski N, Grottke A, Windhorst S, Nörz D, Carstensen L, Staufer K, Hofmann BT, Diehl F, David K, Schumacher U, Nashan B, Jücker M.
    Int J Cancer; 2013 Nov 25; 133(9):2065-76. PubMed ID: 23588885
    [Abstract] [Full Text] [Related]

  • 14. RAD001 offers a therapeutic intervention through inhibition of mTOR as a potential strategy for esophageal cancer.
    Wang ZG, Fukazawa T, Nishikawa T, Watanabe N, Sakurama K, Motoki T, Hatakeyama S, Omori O, Ohara T, Tanabe S, Fujiwara Y, Takaoka M, Shirakawa Y, Yamatsuji T, Tanaka N, Naomoto Y.
    Oncol Rep; 2010 Apr 25; 23(4):1167-72. PubMed ID: 20204306
    [Abstract] [Full Text] [Related]

  • 15. The effect of mTOR inhibition alone or combined with MEK inhibitors on brain metastasis: an in vivo analysis in triple-negative breast cancer models.
    Zhao H, Cui K, Nie F, Wang L, Brandl MB, Jin G, Li F, Mao Y, Xue Z, Rodriguez A, Chang J, Wong ST.
    Breast Cancer Res Treat; 2012 Jan 25; 131(2):425-36. PubMed ID: 21394501
    [Abstract] [Full Text] [Related]

  • 16. Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and AKT.
    Svejda B, Kidd M, Kazberouk A, Lawrence B, Pfragner R, Modlin IM.
    Cancer; 2011 Sep 15; 117(18):4141-54. PubMed ID: 21387274
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of the mammalian target of rapamycin (mTOR) by rapamycin increases chemosensitivity of CaSki cells to paclitaxel.
    Faried LS, Faried A, Kanuma T, Nakazato T, Tamura T, Kuwano H, Minegishi T.
    Eur J Cancer; 2006 May 15; 42(7):934-47. PubMed ID: 16540312
    [Abstract] [Full Text] [Related]

  • 18. The multi-tyrosine kinase inhibitor TKI258, alone or in combination with RAD001, is effective for treatment of human leukemia with BCR-ABL translocation in vitro.
    Eucker J, Zang C, Zhou Y, Li X, Habbel P, Neumann C, Scholz C, Liu H.
    Anticancer Res; 2014 Sep 15; 34(9):4909-14. PubMed ID: 25202073
    [Abstract] [Full Text] [Related]

  • 19. Counteracting autophagy overcomes resistance to everolimus in mantle cell lymphoma.
    Rosich L, Xargay-Torrent S, López-Guerra M, Campo E, Colomer D, Roué G.
    Clin Cancer Res; 2012 Oct 01; 18(19):5278-89. PubMed ID: 22879389
    [Abstract] [Full Text] [Related]

  • 20. Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program.
    Lane HA, Lebwohl D.
    Semin Oncol; 2006 Apr 01; 33(2 Suppl 7):S18-25. PubMed ID: 16730273
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.